Abstract:Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortalities and is projected to become second by 2030. Although major advancements in cancer treatments have improved outcomes for many cancers, the survival rate for PDAC has not improved in nearly four decades. Two primary features make PDAC refractory. First, the highly immunosuppressive tumor microenvironment (TME) plays a crucial role in impeding the innate and effector arms of the immune system to prevent anti-tumor responses. Second, desmoplasia causes formation of fibrotic tissue within and around tumor tissue, which creates a physical barrier for infiltration of anti-tumor immune cells and therapeutics. The goal of this project is to develop viro-immunotherapies against PDAC that target the immunosuppressive TME and desmoplasia by utilizing “armed” oncolytic adenoviruses (OAds) and adoptive T-cell therapy (CAR T-cells). Three transgenes were selected to “arm” the OAd constructs: i.) TGF-beta blocker, ii.) interleukin-7 (IL-7), and iii.) interferon gamma (IFN-gamma). Methods: “Armed” replication-deficient adenovirus (Ad) constructs were first generated to isolate transgene function from oncolytic activity. Each transgene was individually cloned into the E1 region of Ad-5 (WT). Viral particles were amplified in 293 cells and purified via ultracentrifugation using a CsCl gradient. Anti-tumor effects were measured using a syngeneic mouse model. C57BL/6 mice were subcutaneously injected with KPC cells (mouse PDAC cell line), and tumors were treated with Ad constructs via intratumoral injection. Tumors were harvested at various time points and stained for immune cell infiltration and fibrosis. Mesothelin-directed CAR T-cells (meso-CARTs) were injected (tail vein) into NSG mice bearing subcutaneous Panc1 tumors after intratumoral injection of Ad constructs. Results: Tumor growth was significantly inhibited in syngeneic mouse models in the presence of each “armed” Ad construct. Furthermore, significant tumor infiltration of anti-tumor immune cells was induced upon treatment as well as a decrease in fibrosis. Abscopal effects were observed on contralateral tumors after injection of ipsilateral tumors as well as an increase in tumor infiltration of anti-tumor immune cells. Finally, combining meso-CARTs with IFN-gamma-expressing Ad induced the greatest anti-tumor responses. Conclusions: PDAC is very resistant to conventional therapeutics, so utilizing combination strategies seems essential. The findings in this study have broad implications in the field of pancreatic cancer by shedding light on how the TME can be manipulated to enhance anti-tumor effects to aid in the development of more efficient therapeutics against PDAC. Moreover, therapeutics inducing abscopal effects should be highly valued because most PDAC patients die from metastasis. Citation Format: Brett L. Roach, Masato Yamamoto. Treating pancreatic cancer with "armed" oncolytic adenoviruses and adoptive T-cell therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3728.

Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus

Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer

Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity

Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?

Radiofrequency Hyperthermia Enhances Locally Delivered Oncolytic Immuno-Virotherapy for Pancreatic Adenocarcinoma

Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma

Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer

p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death

OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment

The Promise of Immune Stimulatory Oncolytic Viruses

Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?

Oncolytic vaccinia virus armed with 4-1BBL elicits potent and safe antitumor immunity and enhances the therapeutic efficiency of PD-1/PD-L1 blockade in a pancreatic cancer model

Abstract 3720: Utility of oncolytic virus as an immunostimulants and potential for combination therapy with ICIs

Abstract 3728: Treating pancreatic cancer with "armed" oncolytic adenoviruses and adoptive T-cell therapy

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer

[Combined Efficacy of Dendritic Cell Vaccine and Oncolytic Adenovirus in Colorectal Cancer]

CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model

Oncolytic viruses and pancreatic cancer

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

Oncolytic Virotherapy Against the Tumor Microenvironment and Its Potential in Pancreatic Cancer.

An oncolytic system produces oxygen selectively in pancreatic tumor cells to alleviate hypoxia and improve immune activation